Results 21 to 30 of about 42,432 (268)

The effect of SRIH-14 or octreotide on the morphological characteristics of adrenal medulla using newcast [PDF]

Archives of Biological Sciences, 2010
The effects of chronic treatments with either SRIH-14 or octreotide on the adrenal medulla of male Wistar rats were examined. Adult males received subcutaneous (s.c.) injections of 20 μg/100 g body weight of either SRIH-14 or octreotide twice a day for ...
Trifunović Svetlana, Filipović B., Ajdžanović V., Manojlović-Stojanoski Milica, Nestorović Nataša, Sekulić Milka, Milošević Verica   +6 more
doaj   +1 more source

Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future [PDF]

, 2019
In recent decades, the incidence of neuroendocrine tumors (NETs) has steadily increased. Due to the slow-growing nature of these tumors and the lack of early symptoms, most cases are diagnosed at advanced stages, when curative treatment options are no ...
Amthauer, Holger, Jann, Henning, Kayser, Antonin, Roderburg, Christoph, Stueven, Anna Kathrin, Tacke, Frank, Wetz, Christoph, Wiedenmann, Bertram, Wree, Alexander   +8 more
core   +1 more source

The effect of preoperative short-term octreotide treatment to surgery in thyrotropin-secreting pituitary adenomas: a retrospective cohort study

BMC Endocrine Disorders, 2023
Background To prevent thyroid storm and ensure surgical safety, it is imperative to regulate excessive thyroid hormone levels in patients with thyrotropin-secreting pituitary adenomas (TSHoma) prior to surgery.
Runsheng Zhao, Kaiyu Fan, Weiqing Wan
doaj   +1 more source

Circuit dissection of the role of somatostatin in itch and pain [PDF]

, 2018
Stimuli that elicit itch are detected by sensory neurons that innervate the skin. This information is processed by the spinal cord; however, the way in which this occurs is still poorly understood.
AJ Christensen, AJ Todd, Allen C. Dickie, AM Bell, Andrew J. Todd, AP Kardon, B Duan, BL Roth, BN Armbruster, C Peirs, C Solorzano, CE Pichon Le, CL Li, D Bröhl, D Usoskin, DM Bautista, DP Roberson, DR Simmons, E Foster, E Polgár, E Vasyutina, Erika Polgár, F Cevikbas, F Proudlock, GR Dressler, H Petitjean, H Taniguchi, Hanns Ulrich Zeilhofer, Hans Jürgen Solinski, Hendrik Wildner, I Bencivinni, IM Chiu, J Braz, J Chrubasik, Jing Huang, JL Hylden, John S. Riddell, KA Boyle, Kieran A. Boyle, KK Stantcheva, L Cui, L Han, L Li, L Madisen, L Madisen, M Gutierrez-Mecinas, M Gutierrez-Mecinas, M Gutierrez-Mecinas, Mark A. Hoon, Masahiko Watanabe, Mette C. Kriegbaum, MJ Krashes, MQ Nguyen, Noboru Iwagaki, P Taurà, Pang-Yen Tseng, PS Danielian, RJ Mullen, S Sun, Santosh K. Mishra, SE Ross, SK Mishra, SK Mishra, SK Mishra, SM Carlton, SM Carlton, SR Chaplan, T Akiyama, T Hökfelt, T Hökfelt, T Lee, T Yasaka, T Zeyda, V Chapman, VE Abraira, VS Seybold, Y Lu, YG Sun, YG Sun, Z Wiesenfeld-Hallin   +79 more
core   +1 more source

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors [PDF]

, 2017
Background Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited therapeutic options.
Al‐nahhas, A, Ansquer, C, Anthony, L, Azevedo, I, Baudin, E, Baum, Rp, Baum, Rp, Benson, A, Benson, Ab, Berlin, J, Berlin, J, Bodei, L, Brianzoni, E, Bushnell, D, Bushnell, D, Caplin, M, Caplin, M, Chasen, B, Chiara Grana, M, Courbon, F, DELLE FAVE, Gianfranco, Delpassand, E, Delpassand, E, El Haddad, G, Erion, Jl, Freemantle, N, Garbus, S, Giammarile, F, Grande, E, Grande, E, Grossman, A, Hendifar, A, Hendifar, A, Hobday, T, Hobday, T, Jacene, H, Krenning, E, Kulkarni, Hr, Kulke, M, Kulke, Mh, Kunz, Pl, Kvols, L, Kwekkeboom, D, Lebtahi, R, Lopera Sierra, M, Manoharan, P, Mariani, G, Metz, D, Mittra, E, Mittra, E, Mora, J, Mora, J, Morse, M, O'Dorisio, Tm, Pavel, M, Pavel, M, Reed, N, Reed, N, Rindi, G, Ruszniewski, P, Ruszniewski, P, Santoro, P, Scheidhauer, K, Schipper, M, Seregni, E, Seregni, E, Severi, S, Srirajaskanthan, R, Srirajaskanthan, R, Strosberg, J, Strosberg, J, Sundin, A, Taieb, D, Thevenet, T, Van Cutsem, E, Van Cutsem, E, Weber, M, Wolin, E, Wolin, E, Yao, J, Yao, J., Öberg, K, Öberg, K   +82 more
core   +1 more source

Everolimus and long acting octreotide as a volume reducing treatment of polycystic livers (ELATE): study protocol for a randomized controlled trial

Trials, 2011
Background Polycystic liver disease (PLD) is defined as having more than 20 liver cysts and can present as a severe and disabling condition. Most symptoms are caused by the mass effect of the liver size and include abdominal pain and distension.
Chrispijn Melissa, Drenth Joost PH
doaj   +1 more source

Meta-analysis on the effects of octreotide on tumor mass in acromegaly. [PDF]

PLoS ONE, 2012
BACKGROUND: The long-acting somatostatin analogue octreotide is used either as an adjuvant or primary therapy to lower growth hormone (GH) levels in patients with acromegaly and may also induce pituitary tumor shrinkage.
Andrea Giustina, Gherardo Mazziotti, Valter Torri, Maurizio Spinello, Irene Floriani, Shlomo Melmed   +5 more
doaj   +1 more source

Octreotide in Intestinal Lymphangiectasia: Lack of a Clinical Response and Failure to Alter Lymphatic Function in a Guinea Pig Model

Canadian Journal of Gastroenterology, 2004
Intestinal lymphangiectasia, which can be classified as primary or secondary, is an unusual cause of protein-losing enteropathy. The main clinical features include edema, fat malabsorption, lymphopenia and hypoalbuminemia.
S Makhija, P-Y vod der Weid, J Meddings, SJ Urbanski, PL Beck   +4 more
doaj   +1 more source

Efficacy and safety of octreotide treatment for diazoxide‐unresponsive congenital hyperinsulinism in China

Pediatric Investigation, 2020
Importance Octreotide is an off‐label medicine for congenital hyperinsulinism (CHI), but is currently widely used for treatment of patients with CHI. Thus far, variable efficacy and adverse effects have been reported for octreotide. Objective The present
Bingyan Cao, Wu Di, Chang Su, Jiajia Chen, Xuejun Liang, Min Liu, Wenjing Li, Xiaoqiao Li, Chunxiu Gong   +8 more
doaj   +1 more source

Evaluation in vitro and in rats of161Tb-DTPA-octreotide, a somatostatin analogue with potential for intraoperative scanning and radiotherapy [PDF]

, 1995
The characteristics of terbium-161 diethylene triamine penta-acetic acid (DTPA) labelled octreotide with respect to specific binding to somatostatin (octreotide) receptors on rat brain cortex membranes, biological activity, uptake and excretion by ...
Bakker, W.H. (Willem), Bernard, B.F. (Bert), Breeman, W.A.P. (Wouter), Hoflande, L.J. (Leo), Jong, M. (Marcel) de, Krenning, E.P. (Eric), Pluijm, M. (M.) van der, Rolleman, E.J. (Edgar), Setyono-Han, B. (Buddy), Visser, T.J. (Theo)   +9 more
core   +1 more source